Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2026CancerOpen Access

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐3

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAjay K. NookaCSChristopher StrouseSLSarah M. Larson

Discussion

Loading...

Member takes

Overview

Post hoc analysis evaluates elranatamab efficacy and safety in US patients with multiple myeloma, suggesting effective treatment outcomes.

Key Points

  • The aim was to assess the efficacy and safety of elranatamab in a US subgroup of patients with relapsed or refractory multiple myeloma.
  • Post hoc analysis of US patients from MagnetisMM-3 trial involving elranatamab dosing schedules.
  • Patients received 76 mg of elranatamab once weekly with adjustments based on response over 28-day cycles.
  • Inclusion of all BCMA-naive patients who received at least one dose of elranatamab.
  • 66.0% objective response rate with 42.6% achieving complete response or better at 39.6 months median follow-up.
  • Median duration of response was 40.8 months, with progression-free survival at 27.3 months and overall survival at 43.6 months.
  • Common adverse events included infections (70.2%), fatigue (61.7%), and cytokine release syndrome (61.7%).

Cite This Study

Nooka et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff3c0d674f7c03778c9e3https://doi.org/10.1002/cncr.70442
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Elranatamab: Mechanism of Action, Clinical, and Translational Science.2026
  2. 2Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.2026
  3. 3Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium2026 · 6 citations
  4. 4Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025 · 8 citations
  5. 5Impact of elranatamab on quality of life: Patient‐reported outcomes from <scp>MagnetisMM</scp>‐32024 · 13 citations